Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
InflaRx ( (IFRX) ) has provided an update.
On January 15, 2025, InflaRx announced the European Commission’s marketing authorization for their drug GOHIBIC® (vilobelimab) for treating SARS-CoV-2-induced acute respiratory distress syndrome (ARDS) in adults under exceptional circumstances. This approval marks GOHIBIC as the first and only treatment in the EU for this condition, backed by the PANAMO trial’s Phase 3 results, which showed a significant reduction in mortality. InflaRx is exploring commercial partnerships for EU distribution and anticipates no significant impact on its cash flow.
More about InflaRx
InflaRx N.V. is a biopharmaceutical company focused on developing anti-inflammatory therapeutics targeting the complement system. InflaRx’s lead product, vilobelimab, is a first-in-class anti-C5a monoclonal antibody designed to treat various inflammatory conditions. Founded in 2007, the company has offices in Jena and Munich, Germany, and Ann Arbor, MI, USA.
YTD Price Performance: -6.40%
Average Trading Volume: 282,241
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $137.8M
For a thorough assessment of IFRX stock, go to TipRanks’ Stock Analysis page.
